Year 2022 face_with_colon_three
OHSU becomes the first in Oregon to offer focused ultrasound to immediately relieve symptoms of essential tremor, tremor-dominant Parkinson’s disease.
Discovered mechanism provides potential therapeutic targets to slow aging and age-related neurodegenerative diseases.
This is definitely a good find. Helping the brain can help a lot as well as reducing inflammation. I’ll make use of the meditation feature of my Pixel watch.
The brain doesn’t always stay the same. Mental disorders, health issues, and lifestyle habits can alter the way it looks and works.
Fresh from announcing positive Phase 1 trial results for its inflammation-targeting drug candidate, Utah-based biotech Halia Therapeutics is now pursuing Phase 2 studies in a range of indications. The Salt Lake City company’s lead compound is an inhibitor of the NLRP3 inflammasome, a known driver of systemic chronic inflammation, which is linked to conditions including fibrotic disease, Alzheimer’s, Parkinson’s and many others.
Halia is taking a unique approach to the NLRP3 inflammasome by targeting the protein NEK7, which plays a key role in gene’s activity. In preclinical models, the company has shown its approach disrupts the formation of the NLRP3 inflammasome and promotes its disassembly once activated, reducing the overall inflammatory response. In its recent Phase 1 trial, in addition to showing positive safety and tolerability data, Halia’s drug demonstrated positive effects in blood samples taken from healthy volunteers, showing “over 90% suppression of multiple NLRP3-mediated cytokines and chemokines.”
Longevity. Technology: Chronic inflammation is a frequent topic of discussion in longevity circles. The term “inflammaging” refers to the increase of inflammatory cytokines in our bodies as we age, which is linked to chronic morbidity, disability, frailty and premature death. While there is no doubt that Halia believes that its approach can potentially impact many diseases, does the company have aging itself in its sights? We caught up with CEO Dr David Bearss to find out.
Restricting calories is known to improve health and increase lifespan, but much of how it does so remains a mystery, especially in regard to how it protects the brain. Buck Institute for Research on Aging scientists have uncovered a role for a gene called OXR1 that is necessary for the lifespan extension seen with dietary restriction and is essential for healthy brain aging.
“When people restrict the amount of food that they eat, they typically think it might affect their digestive tract or fat buildup, but not necessarily about how it affects the brain,” said Kenneth Wilson, Ph.D., Buck postdoc and first author of the study, published in Nature Communications. “As it turns out, this is a gene that is important in the brain.”
The team additionally demonstrated a detailed cellular mechanism of how dietary restriction can delay aging and slow the progression of neurodegenerative diseases. The work, done in fruit flies and human cells, also identifies potential therapeutic targets to slow aging and age-related neurodegenerative diseases.
Dr. Avshalom Cyrus Elitzur (Hebrew: אבשלום כורש אליצור; born 30 May 1957) is an Israeli physicist, philosopher and professor at Chapman University. He is also the founder of the Israeli Institute for Advanced Physics. He obtained his PhD under Yakir Aharanov. Elitzur became a household name among physicists for his collaboration with Lev Vaidman in formulating the “bomb-testing problem” in quantum mechanics, which has been validaded by two Nobel-prize-winning physicists. Elitzur’s work has sparked extensive discussions about the foundations of quantum mechanics and its interpretations, including the Copenhagen interpretation, many-worlds interpretation, and objective collapse models. His contributions have had a profound impact on both physics and philosophy, influencing debates about measurement, the role of observers, and the ontology of quantum states. Elitzur has also engaged in discussions about consciousness, the arrow of time, and other foundational topics, including a recent breakthrough in bio-thermodynamics and the “ski-lift” pathway.
Elitzur’s Google Scholar page: https://tinyurl.com/5n7a8hd6
Elitzur’s Wikipedia page: https://en.wikipedia.org/wiki/Avshalo…
IAI Article: https://iai.tv/articles/a-radical-new…
Continue reading “Avshalom Elitzur on Biology, Thermodynamics, and Information: A Tutorial” »
A study finds that microglia with mutant TREM2 protein reduce brain circuit connections, promote inflammation, and contribute to Alzheimer’s.
Rapid-acting antidepressants, including ketamine, scopolamine and psilocybin, have been found to have immediate and lasting positive effects on mood in patients with major depressive disorder but how these effects arise is unknown. New research led by the University of Bristol explored their neuropsychological effects and found that all three of these drugs can modulate affective biases associated with learning and memory.
The paper, published in Science Translational Medicine was carried out in collaboration with researchers at Compass Pathways, Boehringer Ingelheim, and the University of Cambridge.
Negative affective biases are a core feature of major depressive disorder. Affective biases occur when emotions alter how the brain processes information and negative affective biases are thought to contribute to the development and continuation of depressed mood.
Jan 11 (Reuters) — The University of Oxford said on Thursday it had begun human testing of an experimental vaccine against the brain-swelling Nipah virus that led to outbreaks in India’s Kerala state and other parts of Asia.
There is no vaccine yet for the deadly virus. Nipah was first identified about 25 years ago in Malaysia and has led to outbreaks in Bangladesh, India and Singapore.
The first participants in the Oxford trial received doses of the vaccine over the last week. The shot is based on the same technology as the one used in AstraZeneca (AZN.L) and Serum Institute of India’s COVID-19 shots.
Ancient DNA helps explain why northern Europeans have a higher risk of multiple sclerosis than other ancestries: It’s a genetic legacy of horseback-riding cattle herders who swept into the region about 5,000 years ago.
The findings come from a huge project to compare modern DNA with that culled from ancient humans’ teeth and bones — allowing scientists to trace both prehistoric migration and disease-linked genes that tagged along.
When a Bronze Age people called the Yamnaya moved from the steppes of what are now Ukraine and Russia into northwestern Europe, they carried gene variants that today are known to increase people’s risk of multiple sclerosis, researchers reported Wednesday.
